June 26 (Reuters) - Bionomics Ltd BNO.AX :
* RESULTS OF AGITATION TRIAL INDICATED THAT BNC210 TREATMENT DID NOT DIFFERENTIATE FROM PLACEBO ON PRIMARY & SECONDARY EFFICACY END POINTS
* TRIAL RESULTS DO NOT SUPPORT FURTHER DEVELOPMENT OF BNC210 FOR TREATMENT OF AGITATION, TO INVEST IN PURSUING DOSE STUDY FOR PTSD